two P-III | PharmaShots

Regeneron’s Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III

Vartika Singh October 16, 2018

Shots: The two P-III study involves assessing of Dupixent + SOC vs PBO (nasal spray alone) in adults with CRSwNP & Dupixent + mometasone furoate nasal spray (MFNS) vs MFNS in patients with bilateral nasal polyps Two P-III (SINUS-24 & SINUS-52) study results: improvement in nasal congestion/obstruction (-1.25 &-1.34 vs -0.38 and -0.45); reduction in […]Read More

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Boehringer Ingelheim Collaborates with Cure Genetics to Develop Next-Generation Liver-Targeted Gene Therapy

Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies

Henlius’ HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China

Kamada to Commercialize Three Biosimilar Products in Israel

Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

The US Government to Purchase Additional Doses of Regeneron’s Casirivimab and Imdevimab to Combat COVID-19

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

Genmab’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA’s Approval for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021

Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer

Tags : two P-III